title: [Effect of some organic and inorganic magnesium salts on lipoprotein state in rats fed with magnesium-deficient diet].
abstract: Low serum magnesium (Mg) concentrations have been reported in patients with atherosclerosis. From the other hand numerous clinical reports suggest the beneficial effects of Mg adjuvant therapy for the treatment of atherosclerosis. The purpose of this present study was to compare the effect of Mg L-aspartate and Mg chloride alone and in combinations with pyridoxine, Mg sulfate and Magne B6 (Mg lactate with pyridoxine) on lipid profile in rats fed with Mg deficient diet. To induce hypomagnesemia, fifty-three rats were placed on a Mg-deficient diet (ICN Biomedicals Inc. Aurora, OH) and demineralized water for 7 weeks. Seven control rats were fed a basal control diet (Mg content = 500 mg/kg) and water (with Mg content 20 mg/l) for equal duration. On the forty-ninth day of Mg-deficient diet, rats were treated one of the six supplementations: Mg chloride, Mg L-aspartate alone and in combinations with pyridoxine, Mg sulphate and Magne B6 (50 mg Mg and 5 mg vitamin B6 per kg). In our study Mg deficiency resulted in increase of triglyceride (by 35.2 %p < 0.0001), LDL (more than fourfold p < 0.0001), total cholesterol (by 38.7% p < 0.0001), apolipoprotein B (by 74.1%, p = 0.0006) levels and decrease in concentration of HDL (by 28.7% p < 0.0001). The non-HDL cholesterol/HDL cholesterol ratio was more than threefold increased (p < 0.0001). Oral magnesium salts led to normalization of lipid state with a return to pre-deficient levels. Magnesium salts in combinations with pyridoxine tended to be significantly more effective as compared with salts without pyridoxine. The hypolipidemic effect of studied salts was comparable with those observed in Magne B6 treatment and significantly higher than in magnesium sulfate treatment.
authors.forename: A A
authors.initials: AA
authors.lastname: Spasov
authors.forename: I N
authors.initials: IN
authors.lastname: Iezgitsa
authors.forename: M V
authors.initials: MV
authors.lastname: Kharitonova
authors.forename: M S
authors.initials: MS
authors.lastname: Kravchenko
mesh_terms: D000818:Animals; D001224:Aspartic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D004032:Diet; D004347:Drug Interactions; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D017616:Magnesium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D008275:Magnesium Deficiency / Q000378:metabolism*; D008297:Male; D011736:Pyridoxine / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D014280:Triglycerides / Q000097:blood; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008079:Lipoproteins, VLDL; D017616:Magnesium Compounds; D014280:Triglycerides; D014803:Vitamin B Complex; D001224:Aspartic Acid; D002784:Cholesterol; D011736:Pyridoxine